← Leaderboards
Rena Xian
Johns Hopkins University
$3,698,061
Attributed
$7,396,122
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,396,122 · 4
By mechanism
R01$4,336,949 · 1
U01$2,742,078 · 2
R21$317,095 · 1
Top collaborators
- Richard F. Ambinder15 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard F. Ambinder$9,273,650
- Richard Bruce Roden$11,133,737
- William George Nelson$34,555,726
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsPlasmaDiagnosisDiagnosticTumorHuman Herpesvirus 4SpecificityChemotherapyAids-Related LymphomaLymphomaSpecimenCharacteristicsBiopsyCause Of DeathSymptomsCostCountryHistologicHodgkin DiseasePatternPerformanceEvaluationAutopsyEnrollment
Grant awards (15)
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$667,061
U01 · FY2025 · CA
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$265,305
U01 · FY2025 · CA
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$65,268
U01 · FY2025 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$848,142
R01 · FY2024 · CA
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$673,198
U01 · FY2024 · CA
Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma$357,595
U01 · FY2024 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$849,329
R01 · FY2023 · CA
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva$713,651
U01 · FY2023 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$104,391
R01 · FY2023 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$814,364
R01 · FY2022 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$104,391
R01 · FY2022 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$816,273
R01 · FY2021 · CA
Clonal Immunoglobulin DNA and Lymphoma Diagnosis$141,985
R21 · FY2021 · CA
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers$800,059
R01 · FY2020 · CA
Clonal Immunoglobulin DNA and Lymphoma Diagnosis$175,110
R21 · FY2020 · CA